UNSPSC 51372029: Metopon hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C18H21NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6O34Q1K8M6. Most nations, for tariff and trade purposes, schedule metopon hydrochloride under HS 29391900 and SITC 54141. As of Q4 2014, METOPON HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metopon hydrochloride bears US NLM identifiers UMLS ID C0956898 and NCI Concept Code C83964. SMILES: C[C@]12C(=O)CC[C@@H]3[C@]14CCN([C@@H]3CC5C4C(C(CC5)O)O2)C.CL.

UNSPSC 51372029 Metopon hydrochloride is a Commodity code that covers opioid pharmaceutical products; however, recent state and local solicitations tagged to this code show minimal direct activity for metopon itself. Instead, the code's recent activity spans broader pharmaceutical procurement, including naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local buyers soliciting under related pharmaceutical codes include county health departments, state health and human services agencies, and cooperative purchasing alliances. The actual work being procured reflects demand for controlled substances and over-the-counter pharmaceutical inventory to support community health initiatives, pharmacy benefit programs, and government employee health plans rather than metopon as a named line item.

Seminole County, Florida issued an IFB (No. IFB60459723LAS, response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a community health building; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with pricing weighted 75 percent on competitiveness and 10 percent on fixed pricing; and the Texas Health and Human Services Commission issued an RFI (No. HHS0017013, due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to improve fulfillment and cost management outside traditional pharmacy benefit manager channels. Recent activity clusters in Florida and the upper Midwest (Minnesota, Oregon) with broader policy-level engagement in Texas, though metopon hydrochloride specifically does not appear as a named commodity in the available solicitations.